All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the advantages of mechanism-based therapies to prevent AML relapse?

During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, What are the advantages of mechanism-based therapies to prevent AML relapse?

What are the advantages of mechanism-based therapies to prevent AML relapse?

In this video, DiNardo provides an overview of mechanism-based therapies for the prevention of relapse in patients with acute myeloid leukemia (AML). She focuses on the incorporation of genomic information in treatment regimen decisions to optimize response for different patient subgroups.

 

Share: